Status:
COMPLETED
Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease
Lead Sponsor:
Medtronic - MITG
Conditions:
End-stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study will be a prospective, interventional, non-randomized, single-center study in 20 ESRD patients on hemodialysis. The study will compare performance of the Clearum HS dialyzer to typical value...
Detailed Description
The study will compare performance to typical values obtained with commercially available dialyzers used for high flux hemodialysis and comparing the Clearum HS dialyzer to the baseline values of a co...
Eligibility Criteria
Inclusion
- ESRD Patients aged 18 years or older
- Patients able to give informed consent (IC) and interested to participate in the study
- Stable (according to the investigator) on hemodialysis for more than 3 months with previous treatments of 3x weekly hemodialysis or hemodiafiltration
- Stable hemoglobin between 10 and 12 g/dl in the most recent two consecutive blood draws
- Stable anticoagulation and ESA regimen with no dosing modifications in the past 1 month
- Patients who have an adequate AVF or graft, capable of providing a blood flow rate of at least 300 mL/min according to sessions conducted in past month
Exclusion
- Patients who have acute renal failure with the chance for recovery.
- Patients who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to PD within the next two months or who require single needle dialysis therapy.
- Pregnant and lactating women.
- Patients with a history of positive serology tests for Hepatitis B surface antigen, positive Hepatitis C total antibody, HIV and syphilis.
- Patients with known hemodynamic instability, anemia (Hgb \< 90 g/L), and/or severe bleeding risks secondary to coagulation disorders.
- Patients with active or ongoing infection per investigator's judgement.
- Patients with a history of solid tumors requiring anti-cancer therapy in the past or next 6 months or a life expectancy less than 1 year or patients with a history of a hematology neoplasm.
- Patients diagnosed with a NYHA Class IV congestive heart failure, or acute coronary syndrome and/or who have suffered a myocardial infarction within three months prior to the start of the study.
- Patients with a history of severe mental disorders.
- Patients who are currently participating or have previously participated in another interventional clinical trial in the past 4 weeks.
- Patients who have had an allergic response to polyarylethersulfone (PAES) or polysulfone membranes or have a history of poor tolerance to dialyzers with synthetic membranes.
- Patients with advanced liver, heart or pulmonary disease as judged by the Investigator
- Patients with any comorbidity possibly conflicting with the study purpose or procedures as judged by the Investigator.
Key Trial Info
Start Date :
April 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 14 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04395131
Start Date
April 3 2020
End Date
August 14 2020
Last Update
September 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DaVita Clinical Research Germany
Düsseldorf, Germany, D-40201